Dosing Begins in Phase 1 Trial of Stem Cell Therapy for Bradykinesia

Dosing Begins in Phase 1 Trial of Stem Cell Therapy for Bradykinesia

282102

Dosing Begins in Phase 1 Trial of Stem Cell Therapy for Bradykinesia

A first patient has been dosed in IMAC Holdings’ Phase 1 clinical trial evaluating its investigational umbilical cord-derived mesenchymal stem cells (MSCs) as a potential treatment for bradykinesia, a common motor symptom of Parkinson’s disease. The infusion treatment was given on Dec. 29, 2020, by the trial’s lead investigator Ricardo Knight, MD, at IMAC’s facility in Brentwood, Tennessee, the company announced. “The first infusion of our proprietary compound is a significant milestone in its development, as well as…

You must be logged in to read/download the full post.